BofA/Merrill Lynch downgraded ResMed (NYSE: RMD) from Buy to Neutral.

Analyst William Dunlop says FY 2018 should be "great" but does not believes the current trajectory is setting to make it so. The analyst comments that market share gains appear difficult.

For an analyst ratings summary and ratings history on ResMed click here. For more ratings news on ResMed click here.

Shares of ResMed closed at $77.48 yesterday.